Operator: Good morning, and welcome to the Cadence Pharmaceuticals Fourth Quarter and Full Year 2012 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Bill LaRue, Senior Vice President and Chief Financial Officer; and Scott Byrd; Senior Vice President and Chief Commercial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the Company, we will open the conference up for questions and answers after the management presentation.
Our first speaker is Bill LaRue. Please go ahead, sir.
William R. LaRue - SVP, CFO: Thank you. Good morning, everyone. Before we begin, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding Cadence's expectations regarding the time when it will be able to offer OFIRMEV in flexible plastic bags and the market for that product and the number of sites participating in the clinical pediatric trial for OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements, which speaks only as of the date hereof.
Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in our business. These risks are detailed under risk factors in our most recent form 10-Q and upcoming form 10-K, as well as elsewhere in our periodic reports and other filings made with the Securities and Exchange Commission from time to time.
All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update the information discussed during this call to reflect events or circumstances after this call.
If anyone has not seen our press release issued today, you can access it on our website at www.cadencepharm.com. We also post and maintain the current version of our corporate presentation on the Investor’s portion of our website under Events and Presentations and then Corporate Overview.
Additionally, this conference call is being webcast through our website and will be archived there for future reference. We use the Investor’s portion of our website as one means of disclosing material non-public information. So we encourage you to monitor our website in addition to following our press releases, SEC filings, and public conference calls and webcasts. Ted?
Theodore R. Schroeder - President and CEO: Thanks, Bill. Good morning everyone, and thank you for joining us today. I will open by providing a brief overview of our accomplishments for the fourth quarter and the full year 2012. Next, Scott will provide an update on our commercial activities and the progress with OFIRMEV, and then Bill will discuss our financial results. Following our prepared remarks, we will open the call to your questions.
Cadence had a great year in 2012 culminated by an excellent fourth quarter. The metric that we track most closely is net product revenue. During the fourth quarter, our net product revenue increased to a record $17.1 million. This level represents an increase of $3.2 million or 23% from the $13.9 million in net product revenue generated during the third quarter of 2012.
Our fourth quarter 2012 revenue exceeded our guidance of $15.9 million to $16.4 million as we ended the year with strong sales growth and momentum. We believe that these results demonstrate a consistent growth story for OFIRMEV sales.
For the full year, we achieved net product revenue of $50.1 million, which was more than four times the $11.5 million in net product revenue generated during OFIRMEV last year in 2011. As we look back at what led to these gains, we believe our early strategy of creating excess and obtaining formulary wins in 2011 set the stage for expansion during 2012. Our enhanced relationships with doctors and pharmacists resulted in a broadening of the number of patients and varieties procedures where OFIRMEV is utilized. As these healthcare professionals have positive patient outcomes and gained familiarity with OFIRMEV, our experience is that the number of vials they use per patient as well as their utilization of the product across their patient populations a while increases.
We are pleased that we increased our efficiency during the fourth quarter of 2012 as evidenced by our gross margins on sales of OFIRMEV improving to 58%. This represents an increase of 200 basis points from the third quarter.
We had two additional positive developments during the fourth quarter that strengthened our balance sheet.
First, we entered into an agreement to waive our option to purchase Incline Therapeutics in order to allow Incline to be sold to a third-party. Incline sale was not completed until early January. So this isn’t reflected in our year end books, but we were able to monetize our investment in Incline such that we received $13.1 million in cash for the waiver of our option plus an additional $1.5 million in cash for the shares of Incline stock that we held. As a reminder, we previously paid a total of $7 million to Incline in connection with our option agreement.
Second, we were able to refinance our credit facility to delay the repayment of principal by an additional 12 months to January 2014. This will defer approximately $11 million of principal payments originally scheduled for 2013.
Within the past two weeks we have taken significant steps to fortify our supply chain for OFIRMEV. Scott will discuss this in greater detail, but we extended our existing supplier arrangement with Lawrence Laboratories, a Bristol-Myers Squibb affiliate, and entered into an agreement with Laboratorios Grifols to supply us with OFIRMEV in flexible plastic bags. These moves coincide with our mutual agreement with Baxter Healthcare to terminate our supply agreement.
At this point, I would like to turn the call over to Scott who will discuss our commercial operations and sales performance during the fourth quarter.
Scott A. Byrd - SVP and Chief Commercial Officer: Thank you. We sold approximately 1.7 million vials of OFIRMEV in the fourth quarter of 2012. This represents an increase of approximately 300,000 vials or 22% as compared to the previous quarter.
This level represents incremental market share gains and OFIRMEV's quarterly IV analgesic unit market share was 2.52% in the fourth quarter versus 2.37% in the third quarter. Since launch in January of 2011 through the end of 2012, we've sold more than 6 million vials of OFIRMEV. We estimate that during this period approximately 2.5 million to 3 million patients have been treated with OFIRMEV using an estimated average of 2 to 2.5 vials per patient.
I'd like to update some of the factors that we believe are key drivers for the growing demand we see for OFIRMEV; growth in the number of new customers, increasing order frequency and the increasing average quantities of product ordered by our customers. We've made improvements in each of these areas during the fourth quarter. The number of unique accounts that have ordered OFIRMEV as of December 31, 2012 increased to 3,750 accounts, which is up approximately 8% from the end of the third quarter of 2012. This represents an increase of nearly 1,500 new accounts over the course of 2012. OFIRMEV is now being used in more than four out of five of the top 2,000 hospitals in the United States, when ranked by the quantity of IV analgesic products purchased. We believe that this is indicative of physician demand for new methods to manage pain and the recognition of the role that OFIRMEV can play in acute pain management.
The number of our repeat customers is also increasing. As of December 31st, over 3,100 accounts or approximately 82% of our customers have placed multiple orders for OFIRMEV. This is an increase of almost 300 accounts more than in the third quarter and an increase of nearly 1,500 repeat customers since the beginning of the year.
Average order frequency for all customers grew to approximately 4.7 orders per quarter during the fourth quarter, an increase of more than 16% versus the previous year. Finally, our average order size rose during the fourth quarter by approximately 7.3% as compared to the third quarter. During 2012, our average order size increased by approximately 40%.
Two years into the launch we are pleased that we continue to fuel sales growth across multiple dimensions, a growing customer base, increasing order sizes and more frequent orders than in prior periods. We believe that the breadth of OFIRMEV adoption represented in these results provides further evidence that physicians and hospitals believe that they can approve acute pain management using OFIRMEV as the foundation of a multi-modal approach.
As we communicate with our customers, we are finding out that more and more of them are including OFIRMEV as part of their standard of care for patients who cannot take oral medications.
The results from our Awareness Trial and Usage studies indicate that as physicians increased their utilization of OFIRMEV, their overall satisfaction and projected future use increases. For example, in the most recent ATU study conducted in December of 2012, physicians satisfaction and intense prescribed scores were the highest we have measured since launch. Anesthesiologists and surgeons indicated that they expect to treat to up to 55% and 60% of their patients, respectively, with OFIRMEV within the next three years.
In that same study, more than three out of four physicians indicated that they are very or extremely likely to recommend OFIRMEV to their colleagues. On this dimension, OFIRMEV ranked first among the seven injectable analgesics included in the research, including morphine, (Sentinel), hydromorphone and ketorolac.
The continued improvement in our key sales metrics and the increasingly positive experience physicians are having with OFIRMEV give us confidence and the growth potential for the product.
Now, I’d like to shift gears and highlight some of the strategic improvements we’ve made in the past two weeks to secure the long-term manufacturing and supply of OFIRMEV. We amended our supply agreement with Lawrence Laboratories, which is a member of the Bristol-Myers Squibb Group of Companies. They are currently acting as our sole supplier for OFIRMEV and among other things, we extended our agreement with them through December 2018 with the opportunity to extend by mutual agreement.
The product is manufactured by a BMS affiliate located in Anagni, Italy, which has manufactured intravenous acetaminophen for more than 10 years for sale and distribution by BMS and its affiliates in a number of countries outside of the U.S. and Canada. They have been the strong partner for us and we are pleased to extend our relationship with them.
We’ve entered into agreement with Grifols to supply us with OFIRMEV in flexible plastic bags. We believe there is a space in the market for IV analgesic products in flexible bags and we think that the new packaging configuration for the product will complement our sales of OFIRMEV in glass vials.
We are planning to submit a supplemental NDA to the FDA seeking approval for the product to be manufactured by Grifols in the second half of 2013. Pending review and subsequent approval of the submission by the FDA, we anticipate the availability of the bag presentation in the second half of 2014. This supply arrangement is for a six year term following the receipt of FDA approval. Grifols has been manufacturing the product in flexible bags for BMS for the distribution in certain markets outside of the U.S. and Canada since 2010, so we expect that this will be another valuable relationship for us and will provide us with a strategic second supply source. Recently we also made a mutual decision with Baxter demining our development and supply agreement for OFIRMEV in glass vials.
I'd like to take this time to thank for sales force and commercial team for their excellent work that led to a significant sales growth in 2012 and great progress towards establishing OFIRMEV as a standard of care in acute pain management. We will strive to continue to grow our business in 2013.
I'll now turn the call over to Bill, who will review the financial results.
William R. LaRue - SVP, CFO: Thanks, Scott. As Ted mentioned, during the fourth quarter of 2012, we achieved net product revenue of $17.1 million and for the full year our net product revenue was $50.1 million. For the fourth quarter of 2012, we reported a net loss of $21.4 million or $0.25 per share compared to net loss of $27.6 million or $0.37 per share for the fourth quarter of 2011. For the 12 months ended December 31, 2012, we reported a net loss of $81 million or $0.95 per share compared to a net loss of $93 million or $1.41 per share for 2011. The net loss for each of these three and 12 months periods ended December 31, 2012 includes impairment charges and a loss on the sale of equipment totaling $8.6 million pertaining to certain manufacturing assets involve with the manufacture of OFIRMEV under our terminated development and supply agreement with Baxter.
Additionally, we recognized disposal costs of approximately 300,000 during the fourth quarter of 2012 for the inventory held during the suspension manufacturing by Baxter. Excluding these one-time charges, our net loss would have been $12.5 million, or $0.15 per share, for the three months ended December 31, 2012 and $72.1 million, or $0.84 per share, for the 12 months ended December 31, 2012.
Our cost of product sales for the three months ended December 31, 2012, was approximately 42% of net product revenue and for the year ended December 31, 2012 it was approximately 46% of net product revenue. The reduction in costs for the fourth quarter of 2012 relative to the full year was primarily attributable to the expedited freight costs and an inventory write-down that occurred during the first quarter of 2012. We also improved efficiencies in 2012, as a result of higher production volumes and we are benefiting from a higher net product selling price as a result of the July 2012 price increase.
Our cost of product sales improved over the year, despite the negative impact of unabsorbed manufacturing costs incurred as a result of idle manufacturing assets located at the facility of one of our third-party manufacturers.
Our research and development expenses were $1.1 million for the three months ended December 31, 2012, which was a decrease of $800,000 as compared to $1.9 million for the same period of 2011.
For the 12 months ended December 31, 2012, our research and development expenses were $6.5 million, which represented a decrease of $2.4 million from the $8.9 million for 2011. These reductions were primarily attributable to a workforce restructuring implemented in the fourth quarter of 2011 that was partially offset in 2012 by pediatric clinical trial expenses and severance obligations related to the departure of two of our officers.
Our selling, general and administrative expenses for the three months ended December 31, 2012 were $20 million, which was a decrease of $500,000 from the $20.5 million for the three months ended December 31, 2011.
For the 12 months ended December 31, 2012, our selling, general and administrative expenses increased by $5.3 million to $86.8 million as compared to $81.5 million for 2011.
The year-over-year increase was mostly attributable to additional legal costs associated or incurred in 2012 for our ongoing intellectual property litigation, increased commissions earned by hospital sales specialists and additional costs incurred for our third-party logistics provider. These increases were partially offset by lower medical affairs and marketing costs.
As of December 31, 2012 we held cash, cash equivalents and short-term investments of $62.1 million and net accounts receivable of $6.2 million. The cash figure does not include the additional $14.6 million of cash we received in connection with the sale of Incline in early January 2013.
I will now turn the call back to Ted.
Theodore R. Schroeder - President and CEO: Thank you Bill. Last year was a great year for Cadence, which was made possible by the hard work of all of our employees. They showed their commitment to establishing OFIRMEV as the foundation of a multi-model approach to acute pain management. Our sales were off to a great start this year and the closing of Incline sale has provided us with additional non-dilutive cash.
As we continue to grow we will seek business development opportunities that are a strategic fit with our company and we aim to continue to expand our sales with OFIRMEV. We are reaffirming our guidance from January and we expect that net product revenue from sales of OFIRMEV for the full year 2013 will range from $94 million to $100 million.
We will now open the call to your questions. Operator?
Operator: Eric Schmidt, Cowen and Company.
Eric Schmidt - Cowen and Company: Congratulations on the continued progress. Scott, I apologize, I just missed what have said about the increase in average order size on a quarter-on-quarter basis?
Scott A. Byrd - SVP and Chief Commercial Officer: Yes, so we had some very nice increases in the average order frequency. You'll see it Eric in our corporate presentation. I'll go back and pull up the numbers for you here in a second, but if you have another question I'll quote it. I think we averaged in Q4 about 92 vials per order over the course of the quarter, which was up from about 85 vials per order in Q3.
Eric Schmidt - Cowen and Company: Unfortunately, my next question is also for you and it pertains to the opportunity for IV bags is that a substantial portion of the market and once you have such product, do you think that's going to be a meaningful additional lever for growth?
Scott A. Byrd - SVP and Chief Commercial Officer: We certainly think it's going to be a growth lever for us. We'll have more to share as we get closer to the launch of the product next year around the magnitude that that represents. We're still of course in the middle of the development as well as some of our marketing planning for it, but there is absolutely no question that this will be a very nice add for many customers out there.
Eric Schmidt - Cowen and Company: In terms of some of the changes you've got on the manufacturing side, Bill, should we expect much gross margin impact and with those changes and the close of the Incline transaction coming up here, still no changes to your guidance for being profitable with current cash?
William R. LaRue - SVP, CFO: Absolutely correct, Eric. We are rock solid in terms of our cash position and resources to get to breakeven, so yes we really did strengthen the balance sheet with those transactions that Ted had mentioned and with respect to the margins, we will continue to see improvement in our margins, so this will not have any negative impact, it will just continuing positive impact and just as a note, without the unabsorbed cost associated with the manufacturing at the Baxter, that equipment, our margins would have been approximately 60% for the fourth quarter, so as you know that's been solid continuing improvement over the course of the year.
Operator: Louise Chen, Guggenheim.
Louise Chen - Guggenheim Partners: I had a few; my first question is if you could provide an update on your move into the non-operative pain segment, may be any metrics you could provide along that opportunity. Secondly as you get closer to profitability, have you completed your NOL analysis yet? And if so, were you able to draw some numbers from that and if not when do you expect to have that. And then lastly, any update on your partnership opportunity in Canada for OFIRMEV?
William R. LaRue - SVP, CFO: This is Bill. Let me take the NOL first because that's kind of the shortest answer of your questions. We are finishing the analysis on our NOLs. We should have that completed in within the next three months and so, as we complete that analysis, we'll make the appropriate disclosures. So, that's about what I can say at this point in terms of the NOL (release), but we'll have that shortly.
Scott A. Byrd - SVP and Chief Commercial Officer: This is Scott. I'll your questions related to the pursuit of the opportunity in non-operative pain. We feel like we still have significant market opportunity, penetration opportunity in the post-op pain space. So, at least for the short to medium term, we're going to continue to focus on deepening our penetration with our surgical customers. As I mentioned we're roughly about 2.5% unit market share, we're just around probably the 10% penetration on surgical procedures as we talked about before and we have in our slide deck, that is relatively modest in comparison to what physicians are indicating that their future utilization is going to reach. They're estimating they will treat north of 50% of their patients sometime over the next three years. So, we want to continue to fuel use there. We will be pursuing the non-operative pain market. As we get closer to that, we'll share some of those details. Just to give you a sense of the size of that opportunity, as best we can tell. The IV analgesic market opportunity for non-operative pain is probably around 30% to 40% of the whole market. So in other words it's about half of the size of the post-op pain opportunity, does that help?
Louise Chen - Guggenheim Partners: It does, and then just on the Canadian partner for OFIRMEV?
Theodore R. Schroeder - President and CEO: Louise, this is ted, we filed as you may recall, we filed the NDS last year so that process is moving forward, the Canadian process is little different than the U.S. but they are actively working on the file, we've received some questions. So we really won’t have any clarity on what our plan will be in Canada so we have approval and can apply for pricing. So our go forward strategy really relies on for the pricing we receive in Canada and then we'll make a decision whether we launch it with Cadence or we seek a partner for distribution in Canada.
Operator: Michael Schmidt, Leerink Swann.
Michael Schmidt - Leerink Swann: I Just had a follow-up on the product in flexible IV bags. I think you said the product has been on the market in Europe for some time what -- how did the product fair on that market or that just to the traditional product and maybe that's something that we could learn in terms of the U.S. opportunity and then what -- is there anything you'd have to do in terms of development or is it just a regulatory filing in the U.S. this year?
Scott A. Byrd - SVP and Chief Commercial Officer: Sure, Michael, to answer you last question first, it's essentially a regulatory filing, the development was actually put in place or was conducted by the Pharmatop, the inventors of IV acetaminophen, so it's is really just getting into shape for the U.S. A GAAP analysis to see if there is anything U.S. required that's different than Europe, but it's essentially a regulatory filing in the U.S. As far as market opportunity, flexible bags are, there are a lot of different products that come in flexible IV bags, it does seem, in some customers is a preferred way to get the products and clearly have fewer problems with breakage and things like that with flexible IV bags. So there is a market for it, our view is that we actually think glass vials will continue to be the dominant product form in the U.S. and that flexible plastic bags will be available for those institutions that prefer the bag and it's a nice line extension to provide some flexibility for customers in the form of the product that they handle. Other than that, there is no difference between the products it's just the container.
Operator: Patti Bank, Discern Securities.
Patti Bank - Discern Securities: Just a few. First for Scott, I joined in a little bit late. Did you talk about the types of surgeries that you’re seeing the most (you said) of OFIRMEV?
Scott A. Byrd - SVP and Chief Commercial Officer: I did not Patti, but we don't have hard data on this. It's mostly experiential, but what we have seen from our field sales es force is utilization that very closely matches the distribution of surgical procedures in the U.S. There are some surgical specialties where we think we’ve got somewhat that garner a greater portion of our overall sales because they tend to use more vials per patient. For example, any open abdominal procedures, cardiothoracic procedures, for example, they tend to use significantly more vials per patient than certainly day procedures or even orthopedics. So on a patient penetration, I think we are pretty well-distributed across all of the surgical procedures. On the business side, as you might expect, those types of procedures where patients are NPO or can’t take oral medications for a number of days and are hospitalized for an extended period of time tend to drive the most vials for us.
Patti Bank - Discern Securities: Then I also want to ask, in terms of upcoming medical meetings and kind of just data news flow, can you give us an idea of what to expect? I think there is Orthopedic Surgeons Meeting coming up in a couple of weeks and I think American Pain Meeting is in early May. Just wanted to get a feel for of presence of OFIRMEV at these meetings and others.
Scott A. Byrd - SVP and Chief Commercial Officer: We’ll have presence at mostly all of those meetings as well as a number of surgical meetings. We're spending a lot more time at meetings for what we would describe as the mid-level health care practitioners and especially the nurses that both support the physicians as nurse practitioners, the PACU nursing communities. So you will see more of the presence for us there. In terms of the news flow, not necessarily any major new presentations of studies at these meetings. Most of our presence will be through satellite symposium presentations, but there will be, I think, continued progress over the course of the year with publications of new data. Our Medical Affairs team has been phenomenal with the publication flow for acetaminophen over the last two years and we’re expecting that to continue. I don't have any specific studies to allude to at this point.
Patti Bank - Discern Securities: So just a follow-up on that, so nothing specific in terms of like cutting down on length of stay, whether it's investigator sponsored or..?
Scott A. Byrd - SVP and Chief Commercial Officer: Well, on almost every meeting, particularly the pharmacy meetings Patti is where you’ll see folks presenting on their institutional experience, there will be some investigator initiated studies finishing up this year, because they are run by the investigators. I can't really and shouldn’t probably give you predictions on when those are going to be completed or presented, but we’ve got hundreds, if not thousands, of hospitals that have done reviews of the products in their institution. Most often the clinical pharmacy colleagues tend to present that information coming out of the medical utilization review. So we’ve seen those at some of the team meetings, but they tend to be more common at the pharmacy meeting. So many, many of those are showing reductions of length of stay, if not most of them. So I think you should expect to continue to see that.
Patti Bank - Discern Securities: Then just a real quick one for Bill, did you mention about the gross margins on the (vaccs), is it similar to the glass vials or is there difference there?
William R. LaRue - SVP, CFO: We think that the margins when everything sells out, we don't expect a material difference in the margins Patti. It will be both consideration of prices as well as COGS, but we think it’ll be in the same range.
Operator: Ami Fadia, UBS.
Ami Fadia - UBS: Most of my questions have been answered. The one that I do have is, if you could give us some clarity on how we should think about R&D and SG&A spending in 2013, and any sort of quarter-over-quarter variation in that, that would be helpful.
William R. LaRue - SVP, CFO: Sure Ami, this is Bill. I think that 2012 operating spending in those categories is pretty representative of what you can expect in the 2013. We have the commercial infrastructure in place. It may move a little bit in terms of categories. We would expect to spend less in G&A with respect to some of the litigation cost that we have associated with the Paragraph IVs. We have the pediatric trial, which is an increasing enrollment and that's a kind of $5 million investment over a two-year period of time, but overall, I think if you look at '12, it's pretty reflective of what you'll see in '13.
Operator: Greg Fraser, Bank of America Securities Merrill Lynch.
Greg Fraser - Banc of America Securities – Merrill Lynch: What was market growth in 4Q? Based on your sales and your market share, looks like growth for the market may have turned positive in the quarter?
Scott A. Byrd - SVP and Chief Commercial Officer: Good question, Greg. It was the largest quarter for the market basket of injectable analgesics that we've seen since 2011. It was almost 65 million units for the quarter, which is pretty substantial growth over the previous quarters for the year. It was up about 15%, for example, over Q3. So, that serves to kind of depress our unit share penetration, but I don't really think it’s terribly relevant to the OFIRMEV adoption rate. The reason is because most of that variation in the market basket is driven by opioid manufacturing, generic manufacturing availability. There were number of shortages during the first part of the year, which most hospitals can manage through that by switching from product-to-product, but as the issues get resolved, they tend to load back in and make sure they’ve got sufficient stock. So, we'll see some variability over time with that, but nothing that I think is terribly relevant for the adoption of OFIRMEV.
Greg Fraser - Banc of America Securities – Merrill Lynch: What are your assumptions for market growth and market share that underlie your OFIRMEV sales target for 2013?
Theodore R. Schroeder - President and CEO: Our expectation is that the overall market for analgesics will remain pretty flat. We've talked about before launch that over the course of OFIRMEV's adoption in the first three to five years, the market will grow. It will likely grow at the rate of adoption of OFIRMEV. That's what we saw in Europe, that's what we’re anticipating here. And the reason is because so many of the opioid products are available in multi-dose vials or packaging that you will tend not to see despite hospitals using less opioids, you’ll tend not to see a significant decrease in the market units. They've still got to crack that vial, they've still got to treat that patient typically with at least one dose somewhere during their stay. So, I would expect it to remain pretty flat, save for example any changes to manufacturing problems that the generic manufacturers might have.
Greg Fraser - Banc of America Securities – Merrill Lynch: Then the last question is on patent case. The case is currently scheduled to go trial in May. Is there anything that you would point to that could delay the trial, I'm not trying to ask about a settlement, but more just about the nuts and bolts of litigation and I guess whether you think the case will be ready for trial in May?
Theodore R. Schroeder - President and CEO: I can say this, we'll be ready for trial in May. We'll be ready to have the bench trial made in front of the judge in May, so I – there isn't anything that I'm aware of that would change that at this point.
Operator: At this time, there are no further questions, so I will turn the conference back to Mr. Schroeder.
Theodore R. Schroeder - President and CEO: Well, thank you very much everyone for joining us on the call today. As you can tell, we are excited about the growth of OFIRMEV and the progress we are making as a company. I appreciate your support and we look forward to providing updates on our commercial progress in the months to come. Thanks everyone.
Operator: Ladies and gentlemen, this concludes our conference call. All parties may now disconnect.